<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469716</url>
  </required_header>
  <id_info>
    <org_study_id>15789</org_study_id>
    <nct_id>NCT00469716</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline-hetastarch in Cardiac Surgery</brief_title>
  <acronym>HH</acronym>
  <official_title>Infusion of Hypertonic Saline-hetastarch in Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiopulmonary bypass(CPB) is associated with increased fluid extravasation and edema
      formation. A continuous infusion of a mixture of hypertonic saline/hydroxyethyl starch
      (HSH)during CPB reduced fluid extravasation and total fluid gain during bypass in an animal
      model. We hypothesize that a continuous infusion of HSH will reduce fluid load and increase
      hemodynamic and respiratory functions in patients undergoing coronary artery bypass with CPB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiopulmonary bypass (CPB) is associated with fluid overload and edema formation
      occasionally resulting in vital organ dysfunction affecting heart, respiratory system ,
      gastrointestinal tract and brain. Hyperosmolar/hyperoncotic preparations (HSH/HSD) have been
      used in cardiac surgery essentially with the aim to mobilize fluid excess and improve
      postoperative cardiorespiratory function.Most studies dealing with the administration of HSD
      or HSH during and after CPB, have used protocols recommended for treatment of severe
      hypovolemia and shock, that is 4 mL/kg as a bolus, given within minutes.In animal experiments
      we have used HSD or HSH, 1 mL/kg/h to a total dose of 4 mL/kg during CPB. The use of HSH/HSD
      reduced the total fluid gain about 50 % and resulted in significantly lower content of tissue
      water in vital organs as heart and lungs. In the actual clinical trial we hypothesize that a
      continuous infusion of HSH will reduce fluid load and increase hemodynamic and respiratory
      functions monitored with the PiCCO system in patients undergoing coronary artery bypass with
      CPB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac output, intrathoracic blood volume, extravascular lung water, global enddiastolic volume</measure>
    <time_frame>12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to extubation, fluid balance, paO2/FiO2- ratio, frequency of atrial fibrillation, cytokines, time to ICU-release and hospital release.</measure>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Postoperative Cardiorespiratory Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective coronary artery bypass graft surgery

        Exclusion Criteria:

          -  Age &lt;18 years or &gt; 75 years

          -  BMI&lt; 18 or &gt; 30

          -  Left ventricular ejection fraction &lt; 40%

          -  Emergency operations

          -  Additional valvular diseases

          -  Impaired renal function

          -  Serum sodium&gt; 145 mmol/l

          -  Hematocrit&lt; 30%

          -  Use of clopidogrel the last 5 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marit Farstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Anesthesia and Intensive Care, Haukeland University Hospital, 5021 Bergen , Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Section for thoracic and cardiovascular surgery, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Mehlhorn U, Geissler HJ, Laine GA, Allen SJ. Myocardial fluid balance. Eur J Cardiothorac Surg. 2001 Dec;20(6):1220-30. Review.</citation>
    <PMID>11717032</PMID>
  </reference>
  <reference>
    <citation>Kumle B, Boldt J, Suttner SW, Piper SN, Lehmann A, Blome M. Influence of prolonged cardiopulmonary bypass times on splanchnic perfusion and markers of splanchnic organ function. Ann Thorac Surg. 2003 May;75(5):1558-64. Retraction in: Ann Thorac Surg. 2011 Jul;92(1):412.</citation>
    <PMID>12735579</PMID>
  </reference>
  <reference>
    <citation>Harris DN, Oatridge A, Dob D, Smith PL, Taylor KM, Bydder GM. Cerebral swelling after normothermic cardiopulmonary bypass. Anesthesiology. 1998 Feb;88(2):340-5.</citation>
    <PMID>9477053</PMID>
  </reference>
  <reference>
    <citation>Harris DN, Bailey SM, Smith PL, Taylor KM, Oatridge A, Bydder GM. Brain swelling in first hour after coronary artery bypass surgery. Lancet. 1993 Sep 4;342(8871):586-7.</citation>
    <PMID>8102722</PMID>
  </reference>
  <reference>
    <citation>McDaniel LB, Nguyen T, Zwischenberger JB, Vertrees R, Uchida T, Kramer GC. Hypertonic saline dextran prime reduces increased intracranial pressure during cardiopulmonary bypass in pigs. Anesth Analg. 1994 Mar;78(3):435-41.</citation>
    <PMID>8109757</PMID>
  </reference>
  <reference>
    <citation>Bueno R, Resende AC, Melo R, Neto VA, Stolf NA. Effects of hypertonic saline-dextran solution in cardiac valve surgery with cardiopulmonary bypass. Ann Thorac Surg. 2004 Feb;77(2):604-11; discussion 611.</citation>
    <PMID>14759446</PMID>
  </reference>
  <reference>
    <citation>Farstad M, Haugen O, Kvalheim VL, Hammersborg SM, Rynning SE, Mongstad A, Nygreen E, Husby P. Reduced fluid gain during cardiopulmonary bypass in piglets using a continuous infusion of a hyperosmolar/hyperoncotic solution. Acta Anaesthesiol Scand. 2006 Aug;50(7):855-62.</citation>
    <PMID>16879469</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluid balance</keyword>
  <keyword>respiratory function</keyword>
  <keyword>cardiac function</keyword>
  <keyword>inflammation</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

